Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting

dc.contributor.author	Korman, Max
dc.contributor.author	Wisløff, Torbjørn
dc.date.accessioned	2017-06-16T11:35:22Z
dc.date.available	2017-06-16T11:35:22Z
dc.date.created	2017-06-02T10:30:37Z
dc.date.issued	2017
dc.identifier.citation	European Heart Journal. 2017, .
dc.identifier.issn	0195-668X
dc.identifier.uri	http://hdl.handle.net/11250/2446262
dc.language.iso	eng
dc.relation.uri	https://academic.oup.com/ehjcvp/article-lookup/doi/10.1093/ehjcvp/pvx010
dc.title	Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
dc.type	Peer reviewed
dc.type	Journal article
dc.source.pagenumber	8
dc.source.journal	European Heart Journal
dc.identifier.doi	10.1093/ehjcvp/pvx010
dc.identifier.cristin	1473693
cristin.unitcode	7502,4,19,0
cristin.unitname	Infeksjonsepidemiologi og modellering
cristin.ispublished	true
cristin.fulltext	original
cristin.qualitycode	2